Tango Therapeutics, INC. (TNGX) — 10-Q Filings

10-Q Filings (6)

• Tango Therapeutics' Cash Dips, WuXi AppTec Legislation Looms — Nov 4, 2025 Risk: high
  Tango Therapeutics, Inc. (TNGX) reported a decrease in cash and cash equivalents to $58.338 million as of September 30, 2025, down from $69.530 million at Decem
• Tango Therapeutics' Q2 Net Loss Widens to $59.8M Amid Soaring R&D Costs — Aug 5, 2025 Risk: high
  Tango Therapeutics, Inc. reported a net loss of $59.8 million for the quarter ended June 30, 2025, a significant increase from the $47.3 million net loss in the
• Tango Therapeutics Files Q1 2025 10-Q — May 12, 2025 Risk: low
  Tango Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business operations. Key financ
• Tango Therapeutics Files Q3 2024 10-Q — Nov 6, 2024 Risk: medium
  Tango Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results, including research and development
• Tango Therapeutics Files Q2 2024 10-Q — Aug 7, 2024 Risk: medium
  Tango Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business ope
• Tango Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk:
  Tango Therapeutics, Inc. (TNGX) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Tango Therapeutics, Inc. filed a 10-Q report for the period ending

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX